遗传性血栓性血栓塞性紫外线 遗传性血栓塞性紫外线
Sanober Nusrat1, Kisha Beg2, Osman Khan2
1Hematology-Oncology Section, Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
遗传性血栓性血栓塞性紫 (hTTP) 是一种罕见的遗传疾病,由ADAMTS13基因突变引起. 治疗重点是通过血输液或即将到来的重组疗法取代ADAMTS13活性.
科学领域:
- 遗传学 遗传学 是一个
- 血液学 血液学 血液学
- 罕见疾病 罕见疾病
背景情况:
- 遗传性血栓性血栓性缺血性紫外线 (hTTP),或Upshaw-Schulman综合征,源于ADAMTS13基因突变.
- 这导致ADAMTS13活性降低,导致超大威莱布兰德因子多元和微型血栓.
- 诊断需要高的怀疑指数,因为不同的临床表现.
研究的目的:
- 审查跨年龄组hTTP的临床表现和差异诊断.
- 讨论目前和新兴的hTTP的预防和治疗策略.
- 通过真实病例来突出HTTP管理的关键方面.
主要方法:
- 关于遗传性血栓性血栓性缺血性紫外线的文献综述.
- 临床表现和诊断方法的分析.
- 对治疗策略的评估,包括血治疗和复合ADAMTS13.
主要成果:
- hTTP表现出各种临床症状,需要仔细诊断.
- 血注射或VIII因子产品是当前的预防措施,在急性发作期间需要加强.
- 再组合ADAMTS13正在接近批准,预计将成为一种高效的治疗方法.
结论:
- 准确的诊断和及时的干预对于管理hTTP至关重要.
- ADAMTS13替代是HTTP治疗的基石.
- 在重组ADAMTS13的进步为hTTP患者提供了改进的治疗选择.
更多相关视频
04:37Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
05:49Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Published on: November 29, 2024
相关概念视频
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
Pedigree Analysis
